SOUTH SAN FRANCISCO, CA--(Marketwire - June 02, 2009) - Theravance, Inc. (NASDAQ: THRX) announced today that Michael W. Aguiar, Senior Vice President and Chief Financial Officer, is scheduled to present at the following investor conferences in June 2009:
Goldman Sachs 30th Annual Global Healthcare Conference Grand Hyatt, New York, New York Tuesday, June 9, 2009 11:55 a.m. ET 8th Annual Needham Life Sciences Conference The New York Palace Hotel, New York, New York Wednesday, June 10, 2009 8:00 a.m. ET
All webcast information will be available on Theravance's web site at www.theravance.com. Listeners are encouraged to visit the site at least 15 minutes prior to the scheduled presentation to register, download and install any necessary audio software.
About Theravance
Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: telavancin for the treatment of serious Gram-positive bacterial infections with Astellas Pharma Inc. and the Horizon program and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency toward drug discovery focused primarily on validated targets, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at www.theravance.com.
THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.
Theravance's presentations will contain certain "forward-looking"
statements as that term is defined in the Private Securities Litigation
Reform Act of 1995 regarding, among other things, statements relating to
goals, plans, objectives and future events. Theravance intends such
forward-looking statements to be covered by the safe harbor provisions for
forward-looking statements contained in Section 21E of the Exchange Act and
the Private Securities Litigation Reform Act of 1995. Examples of such
statements include statements relating to the goals and timing of clinical
studies, statements regarding the potential benefits and mechanisms of
action of drug candidates, statements concerning the timing of seeking
regulatory approval of our product candidates (including with respect to
telavancin statements regarding any expectation that the third-party
manufacturer will successfully address the cGMP issues the FDA noted in the
approvable letter or that regulatory authorities will approve telavancin on
the basis of existing preclinical and clinical data or at all), statements
concerning enabling capabilities of Theravance's approach to drug discovery
and its proprietary insights, and statements regarding expectations for
product candidates through development and commercialization and
projections of revenue and other financial items. These statements are
based on the current estimates and assumptions of the management of
Theravance as of the date of the presentations and are subject to risks,
uncertainties, changes in circumstances, assumptions and other factors that
may cause the actual results of Theravance to be materially different from
those reflected in its forward-looking statements. Important factors that
could cause actual results to differ materially from those indicated by
such forward-looking statements include, among others, risks related to
delays or difficulties in commencing or completing clinical studies, risks
related to the potential that results of clinical or preclinical studies
indicate product candidates are unsafe or ineffective, our dependence on
third parties in the conduct of our clinical studies, delays or failure to
achieve regulatory approvals for, or to successfully launch, product
candidates, risks of relying on third-party manufacturers for the supply of
our product candidates and risks of collaborating with third parties to
develop and commercialize products. These and other risks are described in
greater detail under the heading "Risk Factors" contained in Theravance's
Quarterly Report on Form 10-Q filed with the Securities and Exchange
Commission (SEC) on May 7, 2009 and the risks discussed in our other
periodic filings with the SEC. Given these uncertainties, you should not
place undue reliance on these forward-looking statements. Theravance
assumes no obligation to update its forward-looking statements.
